Annotation Detail
Information
- Associated Genes
- ABL1
- Associated Variants
- ABL1 BCR-ABL
- Associated Disease
- chronic myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- Prior to dasatanib treatment, fifteen imatinib-resistant patients with chronic myeloid leukemia in various phases had the BCR-ABL1 fusion with no secondary variants in at least ten clones generated using peripheral blood RNA. They had no evidence of leukemia (n = 3), complete (9), minor (2), and no (1) best hematologic responses to dasatinib and complete (3), partial (3), minor (2), minimal (2), and no (5) best cytogenetic responses to dasatinib.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/4706
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Chronic Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Dasatinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 16775234
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Dasatinib | Sensitivity | true |